Investing.com - Xenetic Biosciences (NASDAQ: XBIO) reported first quarter EPS of $-0.100, $0.01 worse than the analyst estimate of $-0.090. Revenue for the quarter came in at $490K versus the consensus estimate of $180K.
Xenetic Biosciences's stock price closed at $0.420. It is up 0% in the last 3 months and down -60.560% in the last 12 months.
Xenetic Biosciences saw positive EPS revisions and negative EPS revisions in the last 90 days. See Xenetic Biosciences's stock price’s past reactions to earnings here.
According to InvestingPro, Xenetic Biosciences's Financial Health score is "fair performance".
Check out Xenetic Biosciences's recent earnings performance, and Xenetic Biosciences's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar